Seres Therapeutics (NASDAQ:MCRB) Cut to “Sell” at StockNews.com

StockNews.com cut shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research note released on Tuesday morning.

A number of other analysts have also commented on MCRB. Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 14th. Chardan Capital reissued a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Seres Therapeutics has a consensus rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Stock Performance

Shares of Seres Therapeutics stock opened at $0.73 on Tuesday. The firm has a market cap of $124.30 million, a PE ratio of -3.17 and a beta of 2.11. The business’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $0.84. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $1.53.

Hedge Funds Weigh In On Seres Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC grew its position in shares of Seres Therapeutics by 77.2% in the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after acquiring an additional 788,762 shares during the period. Jane Street Group LLC grew its stake in Seres Therapeutics by 181.4% in the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 37,866 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Seres Therapeutics by 20.4% during the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock worth $218,000 after acquiring an additional 44,461 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Seres Therapeutics by 8.8% during the fourth quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock worth $1,256,000 after acquiring an additional 121,793 shares during the period. Finally, Avantax Advisory Services Inc. grew its position in shares of Seres Therapeutics by 170.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 28,500 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.